Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;145(6):723-729.
doi: 10.4103/ijmr.IJMR_74_17.

Alzheimer's disease: An alternative approach

Affiliations
Review

Alzheimer's disease: An alternative approach

Sadanandavalli Retnaswami Chandra. Indian J Med Res. 2017 Jun.

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative cortical dementia. It starts with memory loss, spatial disorientation in people above the age of 65 yr with a preference to females. Its incidence is expected to increase threefold by 2050. It affects almost one out of ten persons above the age of 65 years. Majority of patients are sporadic, but a very small percentage is autosomal dominant. The pathomechanisms postulated include amyloid cascade hypothesis according to which mutation in amyloid precursor protein causes Aβ aggregation. The next hypothesis is signal transducer and activation of transcription 3 (STAT3) causing aberration in intracellular signalling pathways. Senile plaques and neurofibrillary tangles are other important pathological changes reported. It is observed that dementia research has not yielded the expected result world over, and therefore, the pitfalls with reference to known facts about diagnosis, clinical features, pathogenic mechanisms, assessment of progression, biomarkers, treatment and prevention, as well as brief information on our experiments with relatively inexpensive methods of differentiating the most common types of dementia AD and frontotemporal dementia are discussed.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

References

    1. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11:332–84. - PubMed
    1. Götz J, Ittner LM, Schonrock N. Alzheimer's disease and frontotemporal dementia: Prospects of a tailored therapy? Med J Aust. 2006;185:381–4. - PubMed
    1. Pistollato F, Ohayon EL, Lam A, Langley GR, Novak TJ, Pamies D, et al. Alzheimer disease research in the 21st century: Past and current failures, new perspectives and funding priorities. Oncotarget. 2016;7:38999–9016. - PMC - PubMed
    1. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol. 2008;115:5–38. - PMC - PubMed
    1. Sabbagh JJ, Kinney JW, Cummings JL. Animal systems in the development of treatments for Alzheimer's disease: Challenges, methods, and implications. Neurobiol Aging. 2013;34:169–83. - PubMed

MeSH terms